A 384-well soft agar assay was developed to identify potential novel anticancer compounds. Normally used to detect cell transformation, the assay is used here to quantitate cell proliferation in a 3-dimensional (3-D) anchorage-independent format. HCC827 cells, which are highly sensitive to epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors, were used to develop the method and a set of 9600 compounds used to validate the assay. Results were compared to a monolayer assay using the same compound set. The assay provides a robust method to discover compounds that could be missed using traditional monolayer formats. (Journal of Biomolecular Screening 2007:938-945)
Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science1977;197:461-463.
2.
Hamburger AW: The human tumor clonogenic assay as a model system in cell biology. Int J Cell Cloning1987;5:89-107.
3.
Weaver V., Lelièvre S., Lakins J., Chrenek M., Jones J., Giancotti F., et al: β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell2002;2:205-216.
4.
Bhadriraju K. , Chen CS: Engineering cellular microenvironments to improve cell-based drug testing. DDT2002;7:612-620.
5.
Discher DE, Janmey P., Wang Y-L.: Tissue cells feel and respond to the stiffness of their substrate. Science2005;310:1139-1143.
6.
Abbott A.: Cell culture: Biology's new dimension. Nature2003;424:870-872.
7.
Fukazawa H., Uehara Y.: U0126 reverses Ki-ras-mediated transformation by blocking both mitogen-activated protein kinase and p70 S6 kinase pathways. Cancer Res2000;60:2104-2107.
8.
Fukazawa H., Noguchi K., Murakami Y., Uehara Y.: Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway. Mol Cancer Ther2002;1:303-309.
9.
Fukazawa H., Noguchi K., Masumi A., Murakami Y., Uehara Y.: BimEL is an important determinant for induction of anoikis sensitivity by mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitors . Mol Cancer Ther2004;3:1281-1288.
Fukazawa H. , Mizuno S., Uehara Y.: A microplate assay for quantitation of anchorage-independent growth of transformed cells. Anal Biochem1995; 228:83-90.
12.
Fukazawa H. , Nakano S., Mizuno S., Uehara Y.: Inhibitors of anchorage-independent growth affect the growth of transformed cells on poly(2-hydroxyethyl methacrylate)-coated surfaces. Int J Cancer1996;67:876-882.
13.
Kuppumbatti YS, Bleiweiss IJ, Mandeli JP, Waxman S., Mira-y-Lopez R.: CRBP suppresses breast cancer cell survival and anchorage-independent growth. J Natl Cancer Inst2000;92:475-480.
14.
Bretland AJ , Lawry J., Sharrard RM: A study of death by anoikis in cultured epithelial cells. Cell Proliferation2001;34:379-382.
15.
Zagon IS, McLaughlin PJ: Opioid growth factor (OGF) inhibits anchorage independent growth in human cancer cells. Int J Oncol2004;24: 1443-1448.
16.
Pauli BU, Anderson SN, Mernoli VA, Kuettner KA: Development in an in vitro and in vivo epithelial tumor model for the study of invasion. Cancer Res1980;40:4571-4580.
17.
Kirkels WJ, Pelgrim OE, Hoogenboom Amm, Aalders MW, Debruyne Fmj, Vouus GP, et al: Patterns of tumor colony development over time in soft agar . Int J Cancer1983;32:399-406.
18.
Akiyoshi T. , Wada T., Nakamura Y., Tsuji H.: A simplified method for determination of tritiated thymidine incorporation into cells from tissue in soft agar culture . Jpn J Surg1986;16:235-238.
19.
Pole D., Bowen W.: Determination of cell colony formation in a high content screening assay [Poster 10144]. Poster presented at 10th Annual SBS Conference and Exhibition, Orlando, FL, 2004.
20.
Alley MC, Scudiero DA, Monks A., Hursey ML, Czerwinski MJ, Fine DL, et al: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res1988;48:589-601.
21.
Alley MC, Uhl CB, Lieber MM: Improved detection of drug cytotoxicity in the soft agar colony formation assay through use of a metabolizable tetrazolium salt. Life Sci1982;31:3071.
22.
Ke N., Albers A., Claassen G., Yu DH, Chatterton JE, Hu X., et al: One-week 96-well soft agar growth for cancer target validation . BioTechniques2004;36:826-833.
23.
Amann J., Kalyankrishna S., Massion PP, Ohm JE, Girard L., Shigematsu H., et al: Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res2005;65:226-235.
24.
Shimamura T. , Ji H., Minami Y., Thomas RK, Lowell AM, Shah K., et al. Non-small-cell lungcancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res2006;66:6487-6491.
25.
Xia W., Mullin RJ, Keith BR, Liu LH, Ma H., Rusnak DW, et al: Antitumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways . Oncogene2002;21:6255-6263.
26.
Holtz MS, Slovak ML, Zhang F., Sawyers CL, Forman SJ, Bhatia R., et al: Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood2002;99:3792—3800.
27.
Bianco C., Tortora G., Bianco R., Caputo R., Veneziani BM, Caputo R., et al: Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res2002;8:3250-3258.
28.
Amador ML, Oppenheimer D., Perea S., Maitra A., Cusati G., Iacobuzio-Donahue C., et al: An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res2004;64:9139-9143.
29.
Ciardiello F., Caputo R., Bianco R., Damiano V., Pomatico G., De Placido S., et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor— selective tyrosine kinase inhibitor. Clin Cancer Res2000;6:2053-2063.
30.
Ono M., Hirata A., Kometani T., Miyagawa M., Ueda S., Kinoshita H., et al: Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther2004;3:465-472.
31.
Qian X., LaRochelle WJ, Ara G., Wu F., Petersen KD, Thougaard A., et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Therapeutics2006;5:2086-2095.
32.
Coldren CD, Helfrich BA, Witta SE, Sugita M., Lapadat R., Zeng C., et al: Baseline gene expression predicts sensitivity to gefitinib in non—small cell lung cancer cell lines. MolCancer Res2006;4:521-528.
33.
Senderowicz AM : Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia2001;15:1-9.
34.
Feldman RI, Wu JM, Polokoff MA, Kochanny MJ, Dinter H., Zhu D., et al: Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem2005;280:19867-19874.
35.
Golas JM, Lucas J., Etienne C., Golas J., Discafani C., Sridharan L., et al: SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res2005;65:5358-5364.
36.
Sheets MP, Warrior UP, Yoon H., Mollison KW, Djuric SW, Trevillyan JM, et al: A high-capacity scintillation proximity assay for the discovery and evaluation of ZAP-70 tandem SH2 domain antagonists. J Biomol Screen1998;3:139-144.
